Does Jazz (JAZZ) Have the Potential to Rally 38.94% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 38.9% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
JAZZ or ILMN: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Highly Ranked Medical Stocks to Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX,
These highly ranked medical stocks have the value and essential services that investors may be looking for as tariff concerns and geopolitical tensions have started to rattle markets.
Earnings Estimates Moving Higher for Jazz (JAZZ): Time to Buy?
Jazz (JAZZ) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts See a 29.63% Upside in Jazz (JAZZ): Can the Stock Really Move This High?
The consensus price target hints at a 29.6% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
International Markets and Jazz (JAZZ): A Deep Dive for Investors
Explore Jazz's (JAZZ) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Jazz Pharmaceuticals: Decent 2025 Outlook, Extended Timeline For Zanidatamab
Jazz Pharmaceuticals ended 2024 on a strong note, beating analyst estimates, and the 2025 revenue outlook is slightly below consensus. The delay in zanidatamab's phase 3 trial results is slightly disappointing but could indicate a better-than-expected treatment effect. I continue to see Jazz as a valuation re-rating candidate, driven by zanidatamab and Zepzelca, return to growth and reduced perceptions of the risks for the oxybate franchise.
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations
Jazz reports better-than-expected fourth-quarter results. Its newly issued EPS guidance of $22.50-$24.00 for full-year 2025 surpasses our expectations.
Compared to Estimates, Jazz (JAZZ) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
